AbbVie not seeking accelerated approval of SCLC candidate

AbbVie Inc. (NYSE:ABBV) said Thursday that it will not seek accelerated approval from FDA for Rova-T rovalpituzumab tesirine as third-line treatment of relapsed or refractory small cell lung cancer. The company based its decision on the "magnitude

Read the full 370 word article

User Sign In